RC
NKTR icon

RegentAtlantic Capital’s Nektar Therapeutics NKTR Stock Holding History

RegentAtlantic Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-154
Closed -$245K – 417
2018
Q1 		$245K Buy
+154
New +$198K 0.02% 378
2015
Q1 		– Sell
-133
Closed -$31K – 717
2014
Q4 		$31K Buy
+133
New +$28.4K ﹤0.01% 676

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RegentAtlantic Capital's NKTR Position: Q2 2018 in Review

RegentAtlantic Capital sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 154 shares — an estimated $245K sold.

RegentAtlantic Capital first reported a position in NKTR in Q4 2014 and held it in 2 quarters. The position peaked at $245K in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • RegentAtlantic Capital reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • RegentAtlantic Capital sold 154 Nektar Therapeutics shares in Q2 2018, an estimated $245K.
  • RegentAtlantic Capital first reported a position in Nektar Therapeutics in Q4 2014 and held it in 2 quarters.
  • RegentAtlantic Capital's Nektar Therapeutics position peaked at $245K in Q1 2018.
  • 379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on RegentAtlantic Capital's 13F filing for Q2 2018, filed 31 Jul 2018.